These findings highlight the therapeutic relevance of the E2F1-ASH1L-AS1/APPLE-ERK1/2 axis in HCC and suggest the rationale for precision medicine strategies targeting this pathway. This evidence concerns the gene ASH1L and hepatocellular carcinoma.